BioTime Announces Agreement To Acquire Glycosan BioSystems, Inc.

Published: Feb 14, 2011

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime’s wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.

Back to news